Ankylosing Spondylitis as a Calcium Handling Disorder

This newsletter reveals how ankylosing spondylitis is a single calcium handling disorder driving two opposite skeletal patterns — axial trabecular loss and ectopic enthesophytic new bone — and why correcting calcium signaling reaches both more completely than inflammation suppression alone.

Executive Summary

In ankylosing spondylitis, the axial spine loses trabecular bone while pathological new bone forms at entheses, annular rings, and paraspinal ligaments, leaving the same skeleton both fragile and rigid. Both processes track to disturbed calcium signaling: aberrantly upregulated calcium-sensing receptors on entheseal osteoblasts, cytokine-driven amplification of that signaling, and the noncanonical Wnt/calcium pathway driving osteogenic commitment, so calcium handling, not inflammation alone, sits at the center of the disease. Anti-orbital Ionic Calcium Therapy (AIC) restores normal calcium signaling in affected cells and supports cellular decalcification in areas where calcium is pathologically deposited.

Ankylosing spondylitis: axial bone loss and pathological new bone formation as coexisting calcium-handling failures

Ankylosing spondylitis presents a bone problem that no single mechanism can explain. In the same spine, trabecular bone is lost from the vertebral bodies while abnormal new bone builds up at entheses, annular rings, and paraspinal ligaments, eventually fusing into syndesmophytes. This two-sided pattern has shifted attention toward calcium handling as the common factor behind both ends of the disease.

The calcium-sensing receptor (CaSR) is abnormally overexpressed on entheseal osteoblasts in ankylosing spondylitis, and, once activated, it drives pathological new bone formation rather than protecting trabecular mineral stores. The clinical picture follows directly from this biology: the axial skeleton is both fragile and rigid, with fragility fractures occurring through osteopenic vertebral bodies within a progressively fused spine, so any intervention that addresses only one side of the paradox leaves the other untouched.

Calcium disturbance in ankylosing spondylitis is not limited to the bone surface; it also shapes much of the inflammatory and muscular picture. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) increase CaSR expression in osteoblasts and immune cells, linking mineral sensing directly to NLRP3 inflammasome activation and sustained cytokine amplification. This link has practical weight. It helps explain why anti-cytokine therapy reduces systemic inflammation yet often fails to stop radiographic axial progression: the osteoblast remains activated via a calcium-dependent pathway downstream of the cytokines. A parallel calcium defect shows up in skeletal muscle. Troponin C2 (TNNC2), the calcium-binding protein that triggers fast-twitch muscle contraction, is expressed differently in patients with ankylosing spondylitis than in controls, and the pattern also differs between men and women. The clinical correlate is familiar: paraspinal stiffness, asymmetric axial pain, and sex-associated symptom burden that persist even when inflammatory markers are controlled, a muscle pattern driven by calcium rather than by inflammation.

Viewed through its calcium biology, ankylosing spondylitis behaves as a disease in which calcium signaling fails in two opposite directions within the same skeleton: too weak to protect trabecular bone, too active at entheseal osteoblasts, inflammatory immune cells, and fast-twitch muscle. This two-sided failure is the reason TNF-α and interleukin-17 blockade controls synovitis and enthesitis but does not consistently halt syndesmophyte growth; osteoblast CaSR signaling persists downstream of the cytokine cascade even when inflammation is suppressed, leaving a physiologic gap that standard immunomodulating therapy does not close.

AIC restores calcium signaling at the cell membrane, the endoplasmic reticulum, and the mitochondria, re-coordinating the disordered signals behind both the bone-loss and the new-bone sides of the disease. AIC promotes cellular decalcification, correcting abnormal osteoblast activation by improving CaSR-mediated calcium sensing and directly opposing the drive toward pathological new bone formation. AIC reduces mitochondrial dysfunction and oxidative stress by repairing calcium transfer from the endoplasmic reticulum to the mitochondria, lowering the chronic inflammatory pressure that sustains axial disease. Within this framework, the paradox of ankylosing spondylitis is addressed at its physiologic origin through Anti-orbital Ionic Calcium Therapy, not at either of its downstream skeletal and muscular expressions.

Figure 1. Inflammation drives abnormal bone formation through the calcium-sensing receptor

This figure illustrates how inflammation triggers pathological new bone formation in three animal models of ankylosing spondylitis. In spine tissue, hind paws, and the Achilles tendon attachment, the phosphorylated forms of p65 and Stat3 were increased inside cells carrying the calcium-sensing receptor, exactly at the sites where abnormal bone was forming. In tissue samples from both patients and the same animal models, inflammatory leukocytes accumulated around osteogenic precursor cells, thereby providing the two cell types with an opportunity to communicate.

The accompanying schematic ties these findings together: inflammatory cytokines released by these immune cells hyperstimulate the calcium-sensing receptor via the NF-κB/p65 and JAK/Stat3 pathways, and this overactivated receptor then drives precursor cells toward osteoblast differentiation through phospholipase C gamma signaling, producing the pathological new bone seen in the disease.

Li X, Chen S, Hu Z, Chen D, Wang J, Li Z, Li Z, Cui H, Dai G, Liu L, Wang H, Zhang K, Zheng Z, Zhan Z, Liu H. Aberrant upregulation of CaSR promotes pathological new bone formation in ankylosing spondylitis. EMBO Mol Med. 2020 Dec 7;12(12):e12109. doi: 10.15252/emmm.202012109. Epub 2020 Dec 1. PMID: 33259138; PMCID: PMC7721361.https://creativecommons.org/licenses/by/4.0/

Figure 2. How Wnt signaling shapes bone formation through two parallel pathways

This figure illustrates two Wnt signaling pathways that control bone formation and how inflammation interferes with the canonical pathway. In the canonical pathway, Wnt proteins bind to the Frizzled receptor together with its coreceptor LRP5/6, which protects β-catenin from being broken down and lets it enter the nucleus to switch on genes that drive osteoblast differentiation, raise osteoprotegerin, and lower RANKL; Dickkopf and sclerostin inhibit this pathway, and inflammatory cytokines push their levels up, since TNFα and IL-1β directly induce both, Dickkopf-1 in turn induces sclerostin, IL-17 enhances TNFα and IL-1β, and IL-6 drives B cells into Dickkopf-1–producing plasma cells. In the Wnt/calcium pathway, Wnt binds to Frizzled, activating Disheveled through G-proteins and releasing calcium from the endoplasmic reticulum via phospholipase C and IP3, and this intracellular calcium then activates calcineurin and NFAT to switch on Wnt target genes, driving osteoblast differentiation.

Cici D, Corrado A, Rotondo C, Cantatore FP. Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis. Int J Mol Sci. 2019 Nov 7;20(22):5552. doi: 10.3390/ijms20225552. PMID: 31703281; PMCID: PMC6888549.
https://creativecommons.org/licenses/by/4.0/

Clinical Tips

1. In ankylosing spondylitis, the Achilles tendon and plantar fascia palpate with a firm cord-like band that runs further up the tendon than ordinary mechanical tendon strain does, and the area is tender even at rest. The tendon is hardening with calcium inside, not just inflamed at the surface.

2. Reduced chest expansion in AS is usually described as symmetric, but a side-to-side difference shows up earlier. A tape measure at the fourth rib level reads smaller on one side, marking calcium deposition starting at those rib joints.

3. Tenderness where the collarbone meets the breastbone, and where the upper and lower breastbone meet, marks AS calcium deposition on the front of the chest. Routine spine exams skip this area, but the finding precedes CT-confirmed fusion by years.

4. On deep palpation alongside the spine, AS develops a patchy stiffness, with rigid segments alternating with supple ones, before x-rays show the spine uniformly fused. The pattern reflects each disc ring hardening with calcium on its own schedule rather than the disease moving as a continuous front.

5. The calcium signal at the tendon-bone junction keeps COX-2 running there, which is why anti-inflammatories only partly soften the stiffening under your fingers. AIC works on the calcium signal itself, before the prostaglandin step.

Clinical Snapshot

If you follow ankylosing spondylitis long enough, the same uncomfortable scene keeps coming back. Someone whose blood work looks calm, whose biologic medication is working, whose spine on imaging is steadily becoming more fused, turns up with a small vertebral fracture after a cough, a missed curb, or an unfamiliar mattress. Nobody had expected it. The usual warning signs are not there. Inflammatory markers are unremarkable, MRI shows little or no marrow swelling, and the bone density scan even reads better than it should, because the new bony bridges along the spine, the syndesmophytes, have inflated the number. Underneath that reassuring surface, calcium has been quietly moving in the wrong direction. The spongy mineral inside the vertebra keeps draining out and feeding abnormal deposits at the tendon insertions and along the outer rings of the discs, so the bone behind the bridges thins while the shell around it hardens. Year after year, the spine appears stiffer on scans, and the vertebrae carry less load at the same time.

The task here is not whether the disease is active, but where the calcium is going. On exam, the signs are quieter than the ones we look for in active inflammation. A point of tenderness between the spinous processes that does not fit the fusion pattern already on the films. A change in night pain that is not relieved by movement, the way it usually is. A surprisingly painful response to a load that a stable spine should absorb without complaint. These are calcium traffic signs, not inflammation signs, and they tend to appear before any image confirms what they warn about. Once you start watching for them, the work itself changes. It is no longer about suppressing inflammation. It is about steering where calcium is going. AIC stabilizes calcium handling across the parathyroid, the kidneys, the intestine, and the cell-level signaling that connects them, so the spongy mineral inside the vertebra is not constantly pulled out to feed abnormal deposits elsewhere. It also prompts the thyroid C cells to release the body's own calcitonin, which calms the slow, ongoing breakdown of that inner bone, the very process that hollows the spine out from within while its outside keeps mineralizing.

Conclusion

Ankylosing spondylitis behaves as a single calcium-handling disorder that runs in two opposite directions inside the same skeleton: trabecular mineral is removed from the vertebral bodies, while ectopic mineral builds up at entheses, annular rings, and paraspinal ligaments. The inflammatory cytokines of the disease upregulate the calcium-sensing receptor on osteoblasts and immune cells, shifting the Wnt and calcium arms toward osteoblast formation through phospholipase C, inositol trisphosphate, and the calcineurin/NFAT axis, so that pathological new bone continues to form even when cytokines are blocked. The clinical findings follow directly: a vertebra that thins while its envelope fuses, a firm-band enthesis that is tender without mechanical load, and a low-trauma axial fracture that appears in a spine previously read as stable.

For the practitioner, this means recovery in ankylosing spondylitis cannot rest on inflammation control alone; it also has to address where calcium is being directed and why calcium sensing has shifted toward the wrong tissue compartments. Suppressing cytokines without correcting the calcium-handling step leaves osteoblast over-activation and trabecular bone loss running together, which is why radiographic progression continues even when inflammatory markers look quiet. AIC restores calcium signaling across the cell membrane, the endoplasmic reticulum, and the mitochondria, so the disordered signal that keeps entheseal osteoblasts active and trabecular bone unprotected is corrected at its source rather than at either of its skeletal endpoints. AIC also promotes cellular decalcification through the calcium-sensing receptor, removing mineral from pathological deposition sites while the calcium economy is rebalanced toward the vertebral body, which is exactly the recovery logic a spine that is losing and depositing bone at the same time actually needs.

Join our community today and get instant access to cutting-edge research on AIC Therapy for your patients’ treatments. Thank you for reading.

Server Bozdogan, MD, PhD - ACRI Research Director

Ask the Expert: Submit Your Questions! Have a question about clinical applications? Submit your questions on our website; our experts will address selected topics in the next issue!

Want to learn more about AIC Therapy? Check out our newsletter archive for expert insights and practical tips. Browse past editions of our AIC Therapy for Sleep Disorders. Stay informed and continue learning with carefully curated content designed just for you!